Atypical antipsychotics in child and adolescent psychiatry - Indications apart from schizophrenia;Atypische neuroleptika in der kinder- und jugendpsychiatrischen behandlung - Indikationen außerhalb der schizophrenie mit anwendungshinweisen

Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie

Volumn 33, Issue 3, 2005, Pages 159-168

  Mehler Wex, Claudia ^a   Rothenhöfer, Silke ^a   Warnke, Andreas ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Anorexia nervosa; Atypical antipsychotics; Bipolar disorders; Child and adolescent psychiatry; Disruptive behaviour disorders

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; HALOPERIDOL; LITHIUM; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; ZIPRASIDONE; ZOTEPINE;

AGGRESSION; ANOREXIA NERVOSA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; CHILD PSYCHIATRY; CHILDREN DEPRESSION SCALE; DEPRESSION; DRUG INDICATION; EXTRAPYRAMIDAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HUMAN; IMPULSIVENESS; MANIA; MEDLINE; MONOTHERAPY; NEGATIVE SYNDROME; OBSESSIVE COMPULSIVE DISORDER; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; RATING SCALE; REVIEW; SCHIZOPHRENIA; SCISEARCH; STATE TRAIT ANXIETY INVENTORY; SYSTEMATIC REVIEW; TIC; YALE BROWN CORNELL EATING DISORDER SCALE; YOUNG MANIA RATING SCALE;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; DRUG APPROVAL; HUMANS; MENTAL DISORDERS; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 23344440199     PISSN: 14224917     EISSN: None     Source Type: Journal    
DOI: 10.1024/1422-4917.33.3.159     Document Type: Review

References (50)

1. American Psychiatric Association (2001). Practice Guidelines for the treatment of patients with borderline personality disorder. www.psych.org/ Borderline Practiceguideline.html.
2. Barnett, M. S. (2004). Ziprasidone monotherapy in pediatric bipolar disorder. Case report. Journal of Child and Adolescent Psychopharmacology, 14(3), 471-477.
3. Benedetti, F. Sforzini, L., Colombo, C. & Smeraldi, E. (1998). Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. Journal of Clinical Psychiatry, 59, 103-107.
4. Budman, C. L., Gayer, A., Lesser, M., Shi, Q. & Bruun, R. D. (2001). An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. Journal of Clinical Psychiatry, 62, 290-294.
5. Buitelaar, J. K., van der Gaag, R. J., Cohen-Kettenis, P. & Melman, C. T. M. (2001). A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Journal of Clinical Psychiatry, 62, 239-248.
6. Chang, K. D. & Ketter, T. A. (2000). Mood stabilizer augmentation with olanzapine in acutely manic children. Journal of Child and Adolescent Psychopharmacology, 10, 45-49.
7. DelBello, M. P., Schwiers, M. L., Rosenberg, H. L. & Strakowski S. M. (2002). A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry, 41(10), 1216-1223.
8. DGKJPP, Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie, Berufsverband der Ärzte für Kinder- und Jugendpsychiatrie und Psychotherapie in Deutschland e. V., Bundesarbeitsgemeinschaft der leitenden Klinikärzte für Kinder- und Jugendpsychiatrie und Psychotherapie e. V. (2003). Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. Köln: Deutscher Ärzte Verlag.
9. Dion, Y., Annable, L., Sandor, P. & Choouinard, G. (2002). Risperidone in the treatment of Tourette's syndrome: a double-blind, placebo controlled trial. Journal of Clinical Psychopharmacology, 22, 31-39.
10. Dulz, B. & Welge A. (2003). Zur medikamentösen Anxiolyse bei Borderline-Patienten. Persönlichkeitsstörungen, 7, 253-262.
11. Farde, L., Wiesel, F. A., Halldin, C. & Sedvall, G. (1988). Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry, 45, 71-76.
12. th Congress of the European College of Neuropsychopharmacology, 20.-24. September 2003, Prag.
13. Fisman, S., Steele, M., Short, J., Byrne, T. & Lavallee, C. (1996). Case study: Anorexia nervosa and autistic disorder in an adolescent girl. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 937-940.
14. Frankenburg, F. R. & Zanarini, M. C. (1993). Clozapine treatment of borderline patients: a preliminary study. Comprehensive Psychiatry, 34, 402-405.
15. Frazier, J. A., Biederman J., Tohen, M., Feldman, P. D., Jacobs, T. G., Toma, V., Rater, M. A., Tarazi, R. A., Kim, G. S., Garfield, S. B., Sohma, M., Gonzalez-Heydrich, J., Risser, R. C. & Nowlin, Z. M. (2001). A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. Journal of Child and Adolescent Psychopharmacology, 11, 239-250.
16. Frazier, J. A., Meyer, M. C., Biedermann, J., Wozniak, J., Wilems, T. E., Spencer, T. J., Kim, G. S. M. & Shapiro S. B. (1999). Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 960-965.
17. Herpertz, S. C. (2003). Persönlichkeitsstörungen. In: P. Falkai & F.-G. Pajonk (Hrsg.), Psychotische Störungen. Systematische Therapie mit modernen Neuroleptika (S. 79-91). Stuttgart, New York: Thieme.
18. Kafantaris, V., Coletti, D. J., Dicker, R. & Kane, J. M. (2001). Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 1448-1456.
19. Kowatch, R. A., Suppes, T., Gilfillan, S. K., Fuentes, R. M., Grannemann, B. D. & Emslie, G. J. (1995). Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia. Child and Adolescent Psychopharmacology, 5, 241-253.
20. Kutcher, S., Aman, M., Brooks, S. J., Buitelaar, J., van Daalen, E., Fegert, J., Findling, R. L., Fisman, S., Greenhill, L. L., Huss, M., Kusumakar, V., Pine, D., Taylor, E. & Tyano, S. (2004). International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs): Clinical implications and treatment practice suggestions. European Neuropsychopharmacology, 14, 11-28.
21. Malone, R. P., Cater, J., Sheikh, R. M., Choudhury, M. S. & Delaney, M. A. (2001). Olanzapine versus haloperidol in children with autistic disorder: An open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 40(8), 887-894.
22. Masi, G., Mucci, M. & Millepiede, S. (2002). Clozapine in adolescent inpatients with acute mania. Journal of Child and Adolescent Psychopharmacology, 12(2), 93-99.
23. McDougle, C. J., Kem, D. L. & Posey, D. J. (2002). Case series: Use of ziprasidone for maladaptive symptoms in youths with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 41(8), 921-927.
24. Mehler, C., Wewetzer, C., Schulze, U., Theisen, F., Dittmann, R. W. & Warnke, A. (2001). Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. European Journal of Child and Adolescent Psychiatry, 10, 151-157.
25. Mitchell, J. E., de Zwaern, M. & Roerig, J. L. (2003). Drug therapy for patients with eating disorders. Current Drug Targets - CNS & Neurological Disorders, 2, 17-29.
26. Mukadoles, N. M. & Abali, O. (2003). Quetiapine treatment of children and adolescents with Tourette's disorder. Journal of Child and Adolescent Psychopharmacology, 13(3), 295-299.
27. Newman-Toker, J. (2000). Risperidone in anorexia nervosa. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 941-942.
28. Pavuluri, M. N., Henry D. B., Carbray, J. A., Sampson, G., Naylor, M. W. & Janicak, P. G. (2004a). Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. Journal of Affective Disorders, 82, 103-111.
29. Pavuluri, M. N., Henry, D. B., Devineni, B., Carbray, J. A., Naylor, M. W. & Janicak P. G. (2004b). A pharmacotherapy algorithm for stabilization and maintenance of pediatric bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 43(7), 859-867.
30. Pappadopulus, E., MacIntyre, J. C., Crismon, M. L., Findling, R. L., Malone, R. P., Derivan, A., Schooler, N., Sikich, L., Greenhill, L., Schur, S. B., Felton, C. J., Kranzler, H., Rube, D. M., Sverd, J., Finnerty, M., Ketner, S., Siennick, S. E. & Jensen, P. S. (2003). Treatment Recommendations for the Use of Antipsychotics in Aggressive Youth (TRAAY). Part II. Journal of the American Academy of Child and Adolescent Psychiatry, 42(2), 145-161.
31. Potenza, M. N., Holmes, J. P., Kanes, S. J. & McDougle, C. J. (1999). Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. Journal of Clinical Psychopharmacology, 19(1), 37-44.
32. Poustka, F. (2003). Aggressive Verhaltensstörungen. In: P. Falkai, & F.-G. Pajonk (Hrsg.), Psychotische Störungen. Systematische Therapie mit modernen Neuroleptika (S. 93-105). Stuttgart, New York: Thieme.
33. Powers, P. S., Bannon, Y. & Eubanks, R. (2003). Anorexia nervosa and atypical antipsychotics: effects on weight and psychopathology. Vortrag, Eating Disorders Research Society, Annual Meeting (01.-04.10.2003) Ravello, Italien.
34. Powers, P. S., Santana, C. A. & Bannon, Y. S. (2002). Olanzapine in the treatment of anorexia nervosa: An open trial. International Journal of Eating Disorders, 32, 146-154.
35. Reimherr, F. W. (2002). Dosing and effectiveness of quetiapine in treating children and adolescents. Posterpräsentation, IPS Annual Meeting (9.-13.10.2002) Chicago, Illinois.
36. Riederer, P., Laux, G. & Pöldinger, W. (1998). Neuro-Psychopharmaka. Ein Therapie-Handbuch. Band 4: Neuroleptika. Wien, New York: Springer.
37. Robertson, M. M. (2000). Invited review: Tourette syndrome, associated conditions and the complexities of treatment. Brain, 123, 425-462.
38. Rocca, P., Marchiaro, L., Cocuzza, E. & Bogetto, F. (2002). Treatment of borderline personality disorder with risperidone. Journal of Clinical Psychiatry, 63, 241-244.
39. Roessner, V., Banaschewski, T. & Rothenberger, A. (2004). Therapie der Tic-Störungen. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 32(4), 245-264.
40. Ruggiero, G. M., Laini, V., Mauri, M. C., Ferrari, V., Clemente, A., Lugo, F., Mantero, M., Redaelli, G., Zappulli, D. & Cavagnini, F. (2001). A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Progress in Neuropsyehopharmacology and Biological Psychiatry, 25, 1049-1059.
41. Sallee, F. R., Kurlan, R., Goetz, C. G., Singer, H., Scahill, L., Law, G., Dittman, V. M. & Chappell, P. B. (2000). Ziprasidone treatment of children and adolescents with Tourette's Syndrome: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 39(3), 292-299.
42. Schmider, J. & Hoff, P. (1998). Clozapine in Tourette's syndrome. Journal of Clinical Psychopharmacology, 18(1), 88-9.
43. Schulz, S. C., Camlin, K. L., Berry, S. A. & Jesberger, J. A. (1999). Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biological Psychiatry, 46, 1429-1435.
44. Schur, S. B., Sikich, L., Findling, R. L., Malone, R. P., Crismon, M. L., Derivan, A., MacIntyre, J. C., Pappadopulos, E., Greenhill, L., Schooler, N., Van Orden, K. & Jensen, P. S. (2003). Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY). Part I: A review. Journal of the American Academy of Child and Adolescent Psychiatry, 42(2), 132-144.
45. Simeon, J., Milin, R. & Walker, S. (2002). A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26, 267-275.
46. Soderstrom, H., Rastam, M. & Gillberg, C. (2002). A clinical case series of six extremely aggressive youths treated with olanzapine. European Child and Adolescent Psychiatry, 11(3), 138-141.
47. Soutullo, C. A., Sorter, M. T., Foster, K. D., McElroy, S. L. & Keck, P. E. (1998). Olanzapine in the treatment of adolescent acute mania: a report of 7 cases. Journal of Affective Disorders, 53, 279-283.
48. Turgay, A., Binder, C., Snyder, R. & Fisman, S. (2002). Long-term safety and efficacy of risperidone for the treatment of disruptive behaviour disorders in children with subaverage IQs. Pediatrics, 110, e34.
49. Van Bellingen, M. & De Troch, C. (2001). Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology, 11, 5-13.
50. Zanarini, M. C. & Frankenburg, F. R. (2001). Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry, 62, 849-854.